SciClone Announces New ZADAXIN(R) Anti-Counterfeiting Label

SciClone Announces New ZADAXIN(R) Anti-Counterfeiting Label Wins
Major Industry Award 
FOSTER CITY, CA -- (Marketwire) -- 12/04/12 --  SciClone
Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that its newly
created anti-counterfeiting Pharma-Comb Void label for ZADAXIN has
won the prestigious "Innovator Award" in the annual competition
sponsored by the Tag and Label Manufacturers Institute (TLMI). The
ZADAXIN label, which was created for SciClone by Schreiner MediPharm,
a Germany-based developer and manufacturer of pharmaceutical
specialty labels, is based on an innovative multi-part concept to
ensure product safety and security and to counteract the illegal
practice of refilling previously used medicine vials. 
"Drug counterfeiting is a serious challenge facing the pharmaceutical
industry, public health and regulatory authorities worldwide,
threatening patient safety, compromising the supply and effectiveness
of medical interventions and harming the commercial viability of
important drug therapies," said Friedhelm Blobel, Ph.D., SciClone's
Chief Executive Officer. "SciClone is committed to ensuring patient
safety and security for all of our marketed products. We intend to
continue implementation of an aggressive anti-counterfeiting strategy
for ZADAXIN, and to work in partnership with agencies and health
authorities to combat the crime of trafficking in illegal medicines." 
The ZADAXIN Pharma-Comb Void label is designed to be functionally
destroyed during its initial use. When the label's tear strip --
which also runs around the closure cap -- is removed, the
inscriptions "Opened" and "Used" appear in the film's two indicator
fields. This design is intended to make the undetected reuse of a
glass container with an original label virtually impossible. SciClone
believes that the Pharma-Comb Void label overcomes the limitations of
conventional vial which, even when equipped with overt security
features, such as holograms or color-shifting inks, can be filled a
second time and sold as originals without detection. The new ZADAXIN
label is designed to counteract this practice, and also offers a
valuable added benefit for healthcare professionals: when the label
is opened, a detachable part is released that serves to mark the
syringe accordingly. 
About SciClone  
SciClone Pharmaceuticals is a US-based, China-focused specialty
pharmaceutical company with a product portfolio of therapies for
oncology, infectious diseases and cardiovascular, urological,
respiratory, and central nervous system disorders. SciClone's
ZADAXIN(R) (thymalfasin) is approved in over 30 countries and may be
used for the treatment of hepatitis B (HBV), hepatitis C (HCV) and
certain cancers, and as a vaccine adjuvant, according to the local
regulatory approvals. Besides ZADAXIN, SciClone markets about 14
mostly partnered products in China, including Depakine(R), the most
widely prescribed broad-spectrum anti-convulsant in China;
Tritace(R), an ACE inhibitor for the treatment of hypertension;
Stilnox(R), a fast-acting hypnotic for the short-term treatment of
insomnia (marketed as Ambien(R) in the US); and Aggrastat(R), a
recently-launched interventional cardiology product. SciClone is also
pursuing the registration of several other therapeutic products in
China. SciClone is headquartered in Foster City, California. For
additional information, please visit www.sciclone.com.  
Ambien, Depakine, Stilnox and Tritace are registered trademarks of
Sanofi and/or its affiliates. 
Aggrastat is a registered trademark of Medicure International Inc. in
the United States, and Iroko Cardio LLC in numerous other countries. 
DC Bead is a registered trademark of Biocompatibles UK Limited. 
SciClone, SciClone Pharmaceuticals, the SciClone Pharmaceuticals
design, the SciClone logo and ZADAXIN are registered trademarks of
SciClone Pharmaceuticals, Inc. in the United States and numerous
other countries. 
About Schreiner MediPharm 
Based in the Munich area of Germany, Schreiner MediPharm is a global
leader in the development and manufacture of innovative specialty
labels with value-added benefits that have set the standard in the
healthcare and pharmaceutical industries. Schreiner MediPharm's
expertise is based on over 60 years of experience. The family-owned
company provides specialty labels and label printing services to the
biggest names in the healthcare market in over 20 countries around
the world, including Japan. Schreiner MediPharm's U.S. facility, a
business unit of Schreiner Group LP, is located in Blauvelt, NY. For
additional information, please visit www.schreiner-medipharm.com. 
Corporate Contacts 
Gary Titus 
Chief Financial Officer
650.358.3456
gtitus@sciclone.com  
Jane Green
Investors/Media
650.358.1447
jgreen@sciclone.com